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Background-—The long-term efﬁcacy and safety of alcohol septal ablation (ASA) in patients with highly symptomatic hypertrophic
obstructive cardiomyopathy has been demonstrated. The aim of this study was to evaluate the long-term outcomes of mildly
symptomatic patients with hypertrophic obstructive cardiomyopathy treated with ASA.
Methods and Results-—We retrospectively evaluated consecutive patients enrolled in the Euro-ASA registry (1427 patients) and
identiﬁed 161 patients (5313 years; 27% women) who were mildly symptomatic (New York Heart Association [NYHA] class II)
pre-ASA. The median (interquartile range) follow-up was 4.8 (1.7–8.5) years. The clinical outcome was assessed and compared with
the age- and sex-matched general population. The 30-day mortality after ASA was 0.6% and the annual all-cause mortality rate was
1.7%, which was similar to the age- and sex-matched general population (P=0.62). A total of 141 (88%) patients had resting left
ventricular outﬂow tract gradient at the last clinical checkup ≤30 mm Hg. Obstruction was reduced from 6332 to
1519 mm Hg (P<0.01), and the mean NYHA class decreased from 2.00 to 1.30.1 (P<0.01); 69%, 29%, and 2% of patients
were in NYHA class I, II, and III at the last clinical checkup, respectively.
Conclusions-—Mildly symptomatic hypertrophic obstructive cardiomyopathy patients treated with ASA had sustained symptomatic
and hemodynamic relief with a low risk of developing severe heart failure. Their survival is comparable to the general population. ( J
Am Heart Assoc. 2017;6:e005735. DOI: 10.1161/JAHA.117.005735.)
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T he prognosis in patients with hypertrophic obstructivecardiomyopathy (HOCM) who self-report mild or no
symptoms is signiﬁcantly worse than that of the age- and sex-
matched general US population.1 Furthermore, even in the
absence of cardiac symptoms, severity of the left ventricular
(LV) outﬂow tract obstruction (LVOTO) is independently
associated with a higher risk of adverse clinical outcome.1–5
Based on current guidelines, alcohol septal ablation (ASA)
may only be performed in highly symptomatic HOCM patients
in NYHA class III or IV and in those with recurrent exertional
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syncope associated with a LVOTO ≥50 mm Hg.6,7 In these
patients, ASA has been shown to be very effective in reducing
LVOTO and associated symptoms.8–19 However, data on the
outcomes of ASA in mildly symptomatic patients are scarce.
We examined the long-term outcomes of ASA in patients, who
self-report dyspnea of functional class New York Heart




A total of 1427 consecutive patients (49% women,
58.113.6 years) treated with ASA for HOCM in 11 European
centers were enrolled in the Euro-ASA registry.
We identiﬁed 161 patients (11%; 27% women) with
baseline NYHA class II dyspnea and LVOTO ≥50 mm Hg at
rest or after provocation, who were included in this study.
None reported angina or syncope. Patients were treated with
ASA between January 1996 and May 2016. Some of the
patients have been included in previous reports.4 Informed
consent was given by each patient, and the study was
performed in agreement with The Declaration of Helsinki.
Alcohol septal ablation was performed in mildly symp-
tomatic patients who were diagnosed with HOCM that was
refractory to medical therapy. Because ASA in mildly symp-
tomatic patients is not generally recommended, the proce-
dure was only performed in patients who had signiﬁcantly
reduced quality of life attributed to dyspnea and had a strong
wish for symptomatic improvement. All patients were care-
fully informed about institutional experience with septal
reduction therapy techniques and accepted the risk of the
procedure.
Interventional Procedure and Follow-up
Details of the ASA technique used in the Euro-ASA registry
were published previously.4 Most patients had routine clinical
examination 3 to 6 months post-ASA and subsequently once
every year. The follow-up program included recording of
events, symptoms, physical examination, ECG, and echocar-
diographic examination, including risk stratiﬁcation for sudden
cardiac death (SCD). In patients with an implanted pacemaker
or deﬁbrillator (ICD), the device’s memory and function were
assessed, and ICD therapy was recorded. All clinical adverse
events were conﬁrmed by reviewing the medical records and
respective national registries of deaths. For patients who died
outside the participating hospitals, interviews and/or mail
communications with the next of kin and/or the treating
family doctor were performed to determine the cause of
death.
Deﬁnitions and Study End Points
Clinical outcome post-ASA was assessed and all-cause mor-
tality registered. Sudden death was deﬁned as instantaneous
and unexpected natural death within 1 hour after witnessing
collapse in a previously stable patient or death during sleep. An
appropriate ICD discharge was deﬁned as the ﬁrst post-ASA
device intervention triggered by ventricular tachycardia or
ﬁbrillation. A death that could not be clearly attributed to any
cause was classiﬁed as death of unknown cause.
In this study dealing with mildly symptomatic patients, we
wanted to determine (1) survival post-ASA, as compared to the
sex- and age-matched general population; (2) symptomatic
improvement post-ASA; (3) progression of heart failure symp-
toms post-ASA; and (4) predictors of adverse clinical outcome.
Statistical Analysis
All data were edited and analyzed by 2 independent statis-
ticians (M.M. and E.H.). Student t tests, chi-square tests, and
Kaplan–Meier survival analysis were used, when appropriate.
Expected survival was calculated from age- and sex-speciﬁc
mortality rates obtained from the Human Mortality Database
(University of California, Berkeley, CA and Max Planck
Institute for Demographic Research, Rostock, Germany;
available at www.mortality.org or www.humanmortality.de).
Mortality rates were calculated for each individual and
combined to form an expected summary curve for the
internationally mixed general population. Expected and
observed mortalities were compared by using the 1-sample
log-rank test, which provided a standardized mortality ratio
and the 95% CI. Cox proportional hazards regression was used
to identify predictors of all-cause death and all-cause death or
appropriate ICD discharge or resuscitation. The prognostic
effects of the following parameters were evaluated, ﬁrst in a
univariate model: age at time of ASA; sex; absence of
functional improvement post-ASA; baseline and residual
dyspnea; LVOTO, and septal thickness. Second, variables
with a P<0.15 were entered into a multivariable analysis,
which was performed using a backward step-wise multiple
Cox0s regression. A probability less than 0.05 was considered
to indicate a statistically signiﬁcant result. All reported P
values were 2-sided. The statistical software GraphPad
(release 6.05; GraphPad Software Inc, La Jolla, CA) and Stata
(release 9.2; StataCorp LP, College Station, TX) were used.
Results
Short-Term Outcome
A total of 161 consecutive, mildly symptomatic HOCM
patients (27% women) underwent ASA. Baseline clinical and
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echocardiographic characteristics of the patient cohort are
summarized in Table 1. All procedures were performed with
myocardial contrast echocardiography guidance. Volume of
injected alcohol during ASA was 2.01.1 mL.
One patient (0.6%) died of ventricular ﬁbrillation 2 days
post-ASA. Intra- or periprocedural sustained ventricular
tachycardia/VF requiring electrical cardioversion occurred in
4 (2.5%) additional patients. The 30-day mortality rate was
0.6%.
Of 149 patients without an implanted pacemaker or ICD
pre-ASA, intra- or periprocedural complete heart block was
identiﬁed in 27 (18%), and 14 (9.4%) had a pacemaker
implanted before hospital discharge.
Long-Term Outcomes
None of the 160 (99%) patients who survived the ﬁrst month
post-ASA were lost to follow-up (median follow-up, 4.8
[interquartile range {IQR}, 1.7–8.5; maximum, 16.2] years).
Clinical and echocardiographic data regarding outcomes
>30 days post-ASA are summarized in Table 1.
At last clinical checkup, the resting left ventricular outﬂow
tract (LVOT) gradient was reduced from 6332 to
1519 mm Hg, which translates to a mean LVOTO reduction
of 77%. In 141 (88%) patients, the LVOTO was ≤30 mm Hg at
the last clinical checkup. A total of 111 (69%) patients were in
NYHA class I, 46 (29%) were in NYHA class II, and 3 (2%) were
in NYHA class III at the last clinical checkup.
Fifteen (9.3%) patients underwent repeated septal reduc-
tion therapy attributed to insufﬁcient symptomatic relief; 13
(8.1%) underwent repeated ASA, 3 (1.9%) underwent myec-
tomy, and 1 (0.7%) underwent myectomy after re-ASA. During
the study period, 9 patients (5.6%) had an ICD implanted; 1 for
secondary prevention and 8 for primary prevention according
to current guidelines. Overall, of 18 (11.3%) patients with an
ICD (median age at ASA, 50.011.7 years; 28% women;
median [IQR] follow-up, 3.0 [1.7–8.9] years), 4 (22%) experi-
enced an appropriate ICD discharge (4.5% per year).
A total of 15 (9.3%) deaths occurred during 895 patient-
years of follow-up, which translates to a rate of 1.7 deaths per
100 patient-years. Five of these patients died suddenly, which
converts to a rate of 0.6 sudden deaths per 100 patient-years.
In these patients, ASA was performed at an average age of
61.611.1 years and the mean survival was 5.24.2 years
post-ASA. Causes of death are summarized in Table 2.
Survival free of all-cause mortality at 1, 5, and 10 years
was 97% (95% CI, 93–99), 94% (95% CI, 89–97), and 87% (95%
CI, 78–93), respectively. This survival was comparable to the
expected survival in an age- and sex-matched general
population (P=0.62; Figure 1). According to multivariable
analysis, the independent predictors of all-cause mortality
were age at ASA (hazard ratio [HR], 1.05; 95% CI, 1.00–1.10;
P=0.04) and absence of improvement in NYHA class score at
the last clinical check-up (HR, 3.77; 95% CI, 1.09–13.11;
P=0.04).
Survival free of all-cause mortality combined with the ﬁrst
appropriate ICD discharge or resuscitation at 1, 5, and
Table 1. Clinical and Echocardiographic Characteristics at
Baseline and Follow-up of Mildly Symptomatic Patients With
HOCM Treated With ASA (MeanSD)
Baseline (n=161)
Follow-up >30
Days (n=160) P Values
Age, y 53.412.9 58.912.6
Dyspnea, NYHA class 2.00 1.30.5 <0.01
Episodes of syncope, % 0 5 (3.1) <0.03
LV gradient at rest,
mm Hg
63.331.7 14.619.0 <0.01








ASA indicates alcohol septal ablation; HOCM, hypertrophic obstructive cardiomyopathy;
LV, left ventricular; NYHA, New York Heart Association.





ASA indicates alcohol septal ablation.
Figure 1. Kaplan–Meier survival curves describing all-cause
mortality, including 95% CI and compared to that expected in
the general population after adjustment for age and sex (P=0.62).
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10 years was 97% (95% CI, 93–99), 91% (95% CI, 84–94), and
87% (95% CI, 80–93), respectively. This observed survival free
of (aborted) death was comparable to the expected survival
for the age- and sex-matched general population (P=0.33;
Figure 2). Multivariable analysis performed to identify the
predictors of all-cause mortality including appropriate ICD
discharge and resuscitation found the only independent
predictor to be the absence of NYHA class improvement
(HR, 3.30; 95% CI, 1.14–9.54; P=0.03).
Discussion
Alcohol septal ablation for the HOCM was introduced more
than 2 decades ago,8 and its early use was restricted to highly
symptomatic patients. It has repeatedly been demonstrated
that these patients beneﬁtted symptomatically.4,5,8–19 Some
studies also suggested a positive prognostic inﬂuence of
septal reduction therapy (ASA or surgical myectomy), espe-
cially if post-treatment LVOTO was markedly reduced.5,9,20
The careful therapeutic strategy, focused on the highly
symptomatic and highest risk patients, was mirrored by both
American and European guidelines on hypertrophic cardiomy-
opathy (HCM).6,7 However, recent data have suggested a
signiﬁcant impact of LVOTO on long-term outcome in patients
with HOCM, independent of symptoms.1–3,5,9 This led us to
analyze post-ASA outcomes of patients treated for mild
symptoms and severe LVOTO. The essential ﬁndings of this
study are as follows: (1) Carefully selected patients with mild
symptoms (NYHA class II) and severe LVOTO treated with ASA
had a long-term prognosis similar to that of the sex- and age-
matched general population; (2) these patients were at
minimal risk (2%) for developing severe heart failure (NYHA
class ˃II) symptoms during long-term (median 4.8 years)
follow-up; (3) 70% of patients achieved NYHA functional class
I; (4) resting LVOTO assessed by continuous wave Doppler
echocardiography was reduced by 77% at the last clinical
checkup, and 88% of patients had LVOT gradient ≤30 mm Hg
at the last clinical check-up; and (5) the absence of NYHA
class improvement was independently associated with higher
long-term mortality.
There remains a signiﬁcant knowledge gap in the thera-
peutic strategy for asymptomatic or mildly symptomatic
patients with severe LVOTO. Not surprisingly, the current
therapeutic approach with septal reduction therapy (ASA or
myectomy) is based on evidence obtained exclusively from
highly symptomatic patients; a multicenter North American
registry (n=874; 5516 years; rest gradient, 7038 mm Hg;
78% in NYHA class III/IV) demonstrated a 5-year survival rate
of 86%,21 and previously reported European experience
(n=1275; 5814 years; rest gradient, 6736 mm Hg; NYHA
class 2.90.5) showed a 5-year survival rate of 89%.4 A
5-year survival rate reported in this study is 94%. This
difference was expectable, given that NYHA class pre-ASA
was recently identiﬁed as an independent predictor of all-
cause mortality (HR, 1.5).4
However, scarce data and experience from clinical practice
suggest that severe LVOTO may be harmful irrespective of the
severity of symptoms.1–3,5 This notion was supported by a
study (n=544; 5916 years) from the Mayo Clinic reporting
on the long-term outcome of patients with HOCM who were
free of severe symptoms at baseline.1 Patients with LVOT
gradient >64 mm Hg at baseline had a 10-year survival of
only 53%, and severe LVOTO was an independent predictor of
adverse clinical outcome. Furthermore, death or severe
symptoms occurred in 68% of these patients within 10 years
after the ﬁrst evaluation.1 This ﬁnding is important, especially
in the light of recent studies showing a ≤1% ASA-related
mortality, with an enduring effect on LVOTO and associated
symptoms following the procedure.4,13,22 Thus, on one hand,
LVOTO is considered a risk factor of long-term outcome in
HOCM patients irrespective of their symptoms, and on the
other hand, ASA performed in dedicated centers seems to be
safe and effective in diminishing LVOTO.1–5,8–19,22 The results
of the present study should be weighed against this
background, and although our study has limitations as
discussed below, the results clearly challenge the established
clinical standard of treating only highly symptomatic HOCM
patients with ASA.
The fact that current treatment guidelines on HCM
generally recommend watchful waiting until development of
severe symptoms before invasive treatment parallels estab-
lished practice in patients with severe aortic stenosis.6,7
However, a growing body of evidence suggests that long-term
Figure 2. Kaplan–Meier survival curves describing all-cause
mortality plus the ﬁrst appropriate ICD discharge or resuscitation,
including 95% CIs, and compared to survival expected in the
general population after adjustment for age and sex (P=0.33). ICD
indicates implanted deﬁbrillator.
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outcome in asymptomatic patients with severe aortic stenosis
managed conservatively is dismal, and that earlier invasive
treatment could lead to improved outcomes.23–25 Along this
line, it appears possible that mildly symptomatic HOCM
patients with severe LVOTO could beneﬁt from early invasive
treatment aimed at LVOTO reduction. However, decision
making for early septal reduction therapy in mildly symp-
tomatic patients with HOCM is complex, and these patients
may represent a diverse group. Furthermore, septal reduction
therapy (myectomy or ASA) should only be performed in
dedicated centers that can achieve a procedure-related
mortality rate less than 1%.26
Notably, the European Society of cardiology HCM risk
calculator used to estimate the risk for SCD considers some
mildly symptomatic patients with LVOTO to be eligible for ICD
implantation.27 Although patients after septal reduction
therapy should not be subject to SCD risk evaluation with
this calculator, one can speculate that diminishing LVOTO by
invasive treatment could lower the risk of SCD in some of
these patients.16 This may not only improve survival, but
might also reduce the need for ICD implantation. Such a
clinical scenario is not uncommon, but an adequate thera-
peutic strategy has not yet been determined in these
patients.6,7 Randomized trials would be ultimately required
to determine whether the primary therapeutic goal in such
patients should be invasive reduction of LVOTO and/or ICD
implantation, but, in the meantime, more retrospective data,
such as those presented in the current study, are needed on
outcomes in mildly symptomatic HOCM patients, especially
those with severe LVOTO.
This study has several limitations. First, it was a retro-
spective analysis of prospectively collected data in several
European countries, which is associated with certain inherent
limitations. The centers participating in the Euro-ASA Registry
may differ in patient selection, ASA technique, and post-ASA
evaluation. Nevertheless, some principal tenets were used in
all centers; all ASA procedures were guided by myocardial
contrast echocardiography, and post-ASA assessments
included clinical evaluation, echocardiographic examination,
and device interrogation in all centers. Second, based on
recent real-world data from the US Nationwide Inpatient
Database demonstrating marked differences in ASA safety
between low- and high-volume centers,22 caution is needed
before generalizing the current results, because these
patients were treated in experienced catheterization centers
and subsequently followed in dedicated HCM clinics. More-
over, all patients were carefully selected for ASA, including
presence of septal and mitral apparatus anatomy appropriate
for the procedure. Third, although the Euro-ASA registry is the
largest reported ASA cohort so far, it still included a relatively
small number of mildly symptomatic patients for ultimate
analysis of their clinical outcome. Nevertheless, the present
results are consistent with previously published evidence and
suggest favorable clinical outcome of these patients. Fourth,
this study is based on self-reported level of symptoms.
However, some patients tend to adapt themselves to their
limitation and therefore admit a lower degree of symptom
severity, which might affect baseline characteristics of this
cohort.
Conclusions
Carefully selected, mildly symptomatic HOCM patients with
severe LVOTO treated with ASA in dedicated centers have
long-term prognosis comparable to that of the age- and sex-
matched general population. These patients are at minimal
risk for developing severe heart failure and most of them
achieve long-term functional class NYHA I and LVOT gradient
≤30 mm Hg.
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